1. Market Research
  2. > Pharmaceutical Market Trends
  3. > OTC Pharmaceuticals in Scandinavia

OTC Pharmaceuticals in Scandinavia

  • September 2016
  • -
  • MarketLine
  • -
  • 37 pages

Summary
OTC Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Scandinavia

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Scandinavia

Leading company profiles reveal details of key otc pharmaceuticals market players' global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia otc pharmaceuticals market with five year forecasts

Synopsis
Essential resource for top-line data and analysis covering the Scandinavia otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
What was the size of the Scandinavia otc pharmaceuticals market by value in 2015?

What will be the size of the Scandinavia otc pharmaceuticals market in 2020?

What factors are affecting the strength of competition in the Scandinavia otc pharmaceuticals market?

How has the market performed over the last five years?

Who are the top competitors in Scandinavia's otc pharmaceuticals market?

Key Highlights
The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), medicated skin products (anti-bacterials, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters and bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2015 annual average exchange rates.

The Scandinavian OTC Pharmaceuticals market generated total revenues of $1,308.6m in 2015, representing a CARC of 3.5% between 2011 and 2015.

Analgesics registered the highest sales value in the Scandinavian OTC Pharmaceuticals market in 2015, with total sales of $223.6m, equivalent to 17.1% of the market's overall value.

The breakup of the pharmacy monopoly in Sweden in 2009 has contributed to growth in the largest OTC market in Scandinavia (36.8% in 2015).

Table Of Contents

OTC Pharmaceuticals in Scandinavia
Table of Contents
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market share
Market distribution
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Bayer AG
GlaxoSmithKline Plc
Johnson and Johnson
Novartis AG
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: Scandinavia OTC pharmaceuticals market value: $ million, 2011-15
Table 2: Scandinavia OTC pharmaceuticals market category segmentation: $ million, 2015
Table 3: Scandinavia OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 4: Scandinavia OTC pharmaceuticals market share: % share, by value, 2015
Table 5: Scandinavia OTC pharmaceuticals market distribution: % share, by value, 2015
Table 6: Scandinavia OTC pharmaceuticals market value forecast: $ million, 2015-20
Table 7: Bayer AG: key facts
Table 8: Bayer AG: key financials ($)
Table 9: Bayer AG: key financials (€)
Table 10: Bayer AG: key financial ratios
Table 11: GlaxoSmithKline Plc: key facts
Table 12: GlaxoSmithKline Plc: key financials ($)
Table 13: GlaxoSmithKline Plc: key financials (£)
Table 14: GlaxoSmithKline Plc: key financial ratios
Table 15: Johnson and Johnson: key facts
Table 16: Johnson and Johnson: key financials ($)
Table 17: Johnson and Johnson: key financial ratios
Table 18: Novartis AG: key facts
Table 19: Novartis AG: key financials ($)
Table 20: Novartis AG: key financial ratios

List of Figures
Figure 1: Scandinavia OTC pharmaceuticals market value: $ million, 2011-15
Figure 2: Scandinavia OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 3: Scandinavia OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 4: Scandinavia OTC pharmaceuticals market share: % share, by value, 2015
Figure 5: Scandinavia OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 6: Scandinavia OTC pharmaceuticals market value forecast: $ million, 2015-20
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Scandinavia, 2015
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Scandinavia, 2015
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Scandinavia, 2015
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Scandinavia, 2015
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Scandinavia, 2015
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Scandinavia, 2015
Figure 13: Bayer AG: revenues and profitability
Figure 14: Bayer AG: assets and liabilities
Figure 15: GlaxoSmithKline Plc: revenues and profitability
Figure 16: GlaxoSmithKline Plc: assets and liabilities
Figure 17: Johnson and Johnson: revenues and profitability
Figure 18: Johnson and Johnson: assets and liabilities
Figure 19: Novartis AG: revenues and profitability
Figure 20: Novartis AG: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.